PCK1 and hepatocellular carcinoma: For example, in HCC, the use of auranofin, a TXNRD1(Thioredoxin reductase 1) inhibitor, enhanced the sensitivity of PCK1-deficient HCC cells to sorafenib-induced apoptosis [74].